Access Program Information
<p>The primary purpose of this study is to provide treatment with Nivolumab to subjects with <strong>histologically confirmed stage III (unresectable) or stage IV advanced melanoma</strong> who have progressed on or after prior treatment with an anti-CTLA4-containing therapy and for subjects with known <strong>BRAF mutation</strong>, also progressed on or after treatment with a BRAF inhibitor.</p>
<p> </p>